Anti-CTLA4 treatment has been reported to affect the eye as well as accessory tissues4, with the potential to induce optic neuropathy, myasthenia gravis, keratitis, and corneal injury during administration. The gene discussed is CTLA4; the disease is myasthenia gravis.